J&J Sues HHS to Implement Drug Discount Rebate Plan Changes

Johnson & Johnson is challenging HHS’s objection to its proposed transparency measures, aiming to protect patient access to affordable medications.

The Johnson & Johnson logo is displayed at company offices in Irvine, Calif., on Oct. 17, 2023. Mario Tama/Getty Images

Johnson & Johnson Health Care Systems Inc. (J&J) is suing the U.S. Department of Health and Human Services (HHS) and the Health Resources and Services Administration (HRSA), challenging the agencies’ opposition to its proposed changes to the federal 340B Drug Pricing Program.

The program is designed to help uninsured and low-income patients access affordable medications, according to the complaint filed on Nov. 12 in the U.S. District Court for the District of Columbia.